Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial - The Lancet Diabetes & Endocrinology
Por um escritor misterioso
Descrição
Current concepts regarding Graves' orbitopathy - Bartalena - 2022
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label
Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and
Teprotumumab: Interpreting the Clinical Trials in the Context of
Proposal for Standardization of Primary and Secondary Outcomes in
Frontiers Effects of Non-statin Lipid-Modifying Agents on
PDF) Proof-of-Concept and Randomized, Placebo-Controlled Trials of
Proposal for Standardization of Primary and Secondary Outcomes in
Lipid lowering effects of the CETP inhibitor obicetrapib in
Proposal for Standardization of Primary and Secondary Outcomes in
Long-term efficacy and safety of moderate-intensity statin with
Full article: How can we prevent disease relapse in Graves
Effect of dapagliflozin on the rate of decline in kidney function
de
por adulto (o preço varia de acordo com o tamanho do grupo)
